The manufacture and assessment of tissue microarrays: suggestions and criteria for analysis, with breast cancer as an example

Sarah E. Pinder, John P. Brown, Cheryl Gillett, Colin Purdie, Valerie Speirs, Alastair M. Thompson, Abeer M. Shaaban, NCRI Breast Clinical Studies Grp

    Research output: Contribution to journalArticle

    25 Citations (Scopus)

    Abstract

    Tissue microarray (TMA) is an established and valuable tool, particularly in translational research and clinical trials, allowing resource-efficient use, and high-throughput profiling, of large numbers of tumours. Despite this, there is little evidence, or guidance, on the optimum manufacture, use and assessment of TMAs. Here we review some of the literature, using breast cancer as an example, to highlight good practice and pitfalls in the design and manufacture of TMAs. Issues, such as the size, number, spacing and layout of cores, as well as the assessment and reporting of studies using TMAs are addressed. We make some suggestions regarding these challenges, and propose a checklist of features that should be considered in order to stimulate debate and improve the quality of data produced by TMA analysis.

    Original languageEnglish
    Pages (from-to)169-177
    Number of pages9
    JournalJournal of Clinical Pathology
    Volume66
    Issue number3
    DOIs
    Publication statusPublished - 2013

    Keywords

    • GENE AMPLIFICATION
    • ROUTINE ASSESSMENT
    • ESTROGEN-RECEPTOR STATUS
    • PROTEIN EXPRESSION
    • HER2 STATUS
    • IMAGE-ANALYSIS
    • ENDOCRINE THERAPY
    • HIGH-THROUGHPUT
    • WHOLE SECTIONS
    • IN-SITU HYBRIDIZATION

    Cite this

    Pinder, S. E., Brown, J. P., Gillett, C., Purdie, C., Speirs, V., Thompson, A. M., Shaaban, A. M., & NCRI Breast Clinical Studies Grp (2013). The manufacture and assessment of tissue microarrays: suggestions and criteria for analysis, with breast cancer as an example. Journal of Clinical Pathology, 66(3), 169-177. https://doi.org/10.1136/jclinpath-2012-201091